RNA interference (RNAi) is mediated by small interfering (si) RNAs that target and degrade mRNA in a sequence-speci®c manner. Cellular expression of siRNA can be achieved by the use of expression cassettes driven by RNA polymerase III (pol III) promoters. Here, we demonstrate that a modi®ed tRNA met -derived (MTD) promoter effectively drives the cellular expression of HIV-1-speci®c siRNA. We observed up to 56% greater inhibition of virus production when the MTD promoter was used to drive the expression of short hairpin (sh) RNA targeting the HIV-1 transactivator protein tat compared to cassettes containing other pol III promoters such as H1, U6+1 and U6+27. We conclude that the MTD promoter is ideally suited to drive intracellular expression of HIV-1 speci®c siRNA and may serve as an important component of future RNAi vector delivery systems.
INTRODUCTION
Recent publications have described vector systems using RNA polymerase III (Pol III) promoters to express functional siRNA for silencing a variety of target genes (1±4). Pol III transcripts are abundant in human cells, thus forming the rationale for using Pol III promoters to express high levels of RNA molecules such as ribozymes, antisense compounds and siRNA (2, 5) . To date, two different Pol III promoters, the human U6 small nuclear (sn) RNA and the human H1 promoter have been widely used in siRNA expression vectors (1, 6) . U6 snRNA plays a central role in processing premature RNA species (7) . The H1 transcript is a component of human nuclear RNase P, an enzyme that cleaves tRNA precursors to produce mature 5¢-termini (8) . Pol III promoters are classi®ed into three different categories (Type I, II and III) based upon the composition of the promoter elements and their position relative to the transcriptional start site (9) . Type III promoters such as U6 and H1 have a compact and relatively simple organization and are located upstream of the transcribed region. Transcription is terminated within a stretch of four to six uridines yielding small RNA transcripts with a de®ned 3¢ overhang. This structural feature was shown to be critical for the function of siRNA synthesized in vitro (10) .
Type II promoters, such as tRNA promoters, have been widely used to express ribozymes and antisense RNA (11±15). Previous studies have shown that the tRNA promoter is more effective in driving the expression of ribozymes than other Pol II and Pol III promoters (16) . Optimization of the met tRNA transcription unit increased the expression of transcripts by >100-fold (5, 15) . In this study, we compared the utility of type II and type III RNA Pol III promoters in mediating HIV-1 speci®c RNAi. We incorporated a modi®ed human tRNA metderived (MTD) promoter into a short hairpin RNA (shRNA) expression cassette. We designed siRNA that targeted exon-1 of the HIV-1 tat gene which encodes a transactivator protein critical for viral replication (17) . The expression levels and antiviral ef®cacy of tat shRNA driven by the MTD promoter were determined and compared to those obtained using other promoters including H1, U6, U6+1 and U6+27. Our experiments demonstrate that the MTD promoter was most effective in mediating HIV-1 speci®c RNAi.
MATERIALS AND METHODS

siRNA sequences
siRNA with the following sense and antisense sequences were used: tat (sense), 5¢-CUG CUU GUA CCA AUU GCU AdTdT-3¢; tat (antisense), 5¢-UAG CAA UUG GUA CAA GCA GdTdT-3¢. Synthetic RNA was purchased from Dharmacon Research (Lafayette, CO, USA) and was deprotected and annealed according to the manufacturer's instructions.
Construction of shRNA expression cassettes
The human H1 promoter and different versions of the human U6 promoter (U6, U6+1, U6+27) were PCR-ampli®ed from genomic DNA isolated from HeLa cells. Primers used for the  generation of the H1 promoter were H1S, 5¢-CCA TGG AAT  TCG AAC GCT GA-3¢, and H1AS, 5¢-GGG AAA GAG TGG  TCT CAT AC-3¢ and those used for the various U6 promoters  were: U6S, 5¢-AAG GTC GGG CAG GAA GA-3¢, U6AS, 5¢-GGT GTT TCG TCC TTT CCA C-3¢, U6+1AS, 5¢-CGG  TGT TTC GTC CTT TCC AC-3¢ and U6+27AS, 5¢-TAG TAT  ATG TGC TGC CGA AGC GAG CAC GGT GTT TCG TCC  T-3¢, respectively. The MTD promoter was generated by  overlap extension PCR (18) using the following primers: TS,  5¢-TGC TGG GCC CAT AAC CCA GAG GTC GAT GGA  TCG AAA CCT GCG CCA CTC CTG ATG AGC CTC TAG  ACA CTC TCG AGG GCG AT-3¢, TAS, 5¢-ATC GCC CTC  GAG AGT GTC TAG AGG CTC ATC AGG AGT GGC GCA  GGT TTC GAT C CA TCG ACC TCT GGG TTA TGG GCC  CAG CA-3¢ , Not-TS, 5¢-GCG GCC GCG GCA GAA CAG TCG AGT GG C GCA GCG GAA GCG TGC TGG GCC CAT AAC-3¢, and Not-TAS, 5¢-GCG GCC GCA TCG ATG TTA GGA GAT CTA AAC AGA ACA GTA TCG CCC TCG AGA GTG TCT AG-3¢.
To generate the H1 and U6 promoter cassettes with appropriate restriction sites, second round PCRs were performed on the respective ®rst round PCR products. For the H1 promoter cassette, the primers were NH1, 5¢-GTG ACA GCG GCC GCC CAT GGA ATT CGA ACG CT-3¢ and H1MCS, 5¢-CAA CAG GCG GCC GCA TCG ATG TTA GGA GAT CTA AAA ACT CGA GAT TTC ATC TAG AGG GAA AGA GTG GTC TCA-3¢. For the U6 promoter cassette, PCR was performed with primers NU6, 5¢-GTG ACA GCG GCC GCA AGG TCG GGC AGG AAG A-3¢ and U6MCS, 5¢-CAA CAG GCG GCC GCA TCG ATG TTA GGA GAT CTA AAA ACT CGA GAT TTC ATC TAG AGG TGT TTC GTC CTT TCC-3¢.
PCR products containing each promoter were cloned into the NotI site of the shuttle vector pCMV-MCS (Stratagene, Valencia, CA, USA) yielding the constructs pCMV-MTD-MCS, pCMV-H1-MCS, pCMV-U6-MCS, pCMV-U6+1-MCS and pCMV-U6+27-MCS. A neomycin resistance cassette, including the SV40 early promoter and the SV40 polyadenylation signal, was inserted into the BglII and ClaI sites of each of the pCMV-MCS constructs. The resulting siRNA expression cassettes were subcloned into the NotI site of pAAV-MCS (Stratagene).
A CMV promoter-driven shRNA expression cassette was generated by subcloning the CMV promoter, including the multiple cloning site, polyadenylation signal and neomycin selection cassette from pcDNA3.1 (Invitrogen, Carlsbad, CA, USA), into Mlu and Bst 1107 sites previously introduced into pAAV-MCS. Two complementary oligonucleotides containing 21-nt tat sequences 5¢-CTA GAA CTG CTT GTA CCA ATT GCT ATT AGG ATC AAT AGC AAT TGG TAC AAG CAG TTTTTC-3¢ and 5¢-TCG AGA AAA ACT GCT TGT ACC AAT T GC TAT TGA TCC TAA TAG CAA TTG GTA CAA GCA GTT CTA GT-3¢ were annealed and cloned into the XbaI and XhoI sites of pAAV-MTD-MCS-Neo, pAAV-H1-MCS-Neo, pAAV-U6-MCS-Neo, pAAV-U6+1-MCS-Neo, pAAV-U6+27-MCS-Neo and pAAV-pCMV-MCS-Neo. In addition, a control vector, pAAV-MTD-luc-Neo, was generated which synthesizes shRNA targeting the luciferase gene. All Pol III shRNA expression cassettes included a hexaloop (AGGATC) separating tat sense and antisense sequences followed by a 5T termination signal (Fig. 1 ). 
Cell culture and transient transfections
Real-time RT±PCR
Total cellular RNA was extracted using Trizol reagent (Invitrogen) and treated with RQ1 DNase (Promega, Madison, WI) according to the manufacturer's protocol. DNase-treated RNA (1 mg) was added to a reverse transcription (RT) reaction containing Powerscript Reverse Transcriptase (Clontech, Palo Alto, CA), 1 mM of each dNTP, 1Q First-Strand buffer (Clontech), 200 ng random hexamers (Promega), 10 U RNasin (Promega). Reverse transcription was performed at 42°C for 1 h followed by heat-inactivation of the RT enzyme at 70°C for 15 min. cDNA (2 ml) was added to 48 ml of PCR mix containing 1Q Titanium Taq PCR buffer (Clontech), 20 pmol of sense primer TS, 5¢-CAT CCA GGA AGT CAG CCT A-3¢, and antisense primer TAS, 5¢-TTC CTG CCA TAG GAG ATG C-3¢, 1 mM dNTPs, SYBR Green I (1:75 000), 10 nM¯uorescein, and 1Q Titanium Taq polymerase (Clontech). For RNA normalization, a GAPDH-PCR was performed with the same PCR reagents except for the primers which were G1, 5¢-GAT TTC TCC CCC TTC TGC TGA TG-3¢ and G2, 5¢-CCT TGG CTG GGG GTG CTA A-3¢. An external standard curve was created using RNA transcripts of tat exon-1 which were generated with the MEGAscript in vitro transcription kit (Ambion, Austin, TX). Real-time PCR was carried out in an iCycler (Bio-Rad, Hercules, CA) using the following thermal cycling pro®le: 95°C 1 min, followed by 35 cycles of ampli®cation (95°C 15 s, 61°C 30 s, 68°C 30 s).
Northern blot
Forty-eight hours after transfection, RNA samples were prepared from 293T cells using Trizol reagent (Invitrogen). To determine the level of shRNA expression obtained by each individual promoter, 20 mg of total RNA was separated by electrophoresis on a 10% polyacrylamide/7 M urea gel and electroblotted for 4 h at 400 mA. To detect HIV-1 RNA degradation mediated by tat-speci®c siRNA, 10 mg of RNA was denatured in glyoxal sample loading dye (Ambion), separated on a 1.2% agarose gel and transferred using the Turboblotter system (Schleicher & Schuell, Dassel, Germany). Tubulin mRNA was used as an internal standard. In all cases, RNA was blotted on a Zeta-Probe GT membrane (Bio-Rad) and immobilized by UV crosslinking. Hybridization was carried out at 42°C for siRNA and at 65°C for HIV-1 mRNA detection using Ultrahyb-Oligo Hybridization Buffer (Ambion). HIV-1 speci®c shRNA was probed with a 32 P-labeled tat antisense oligonucleotide. HIV-1 RNA and tubulin mRNA were probed with 32 P-labeled gag and tubulin DNA probes, respectively. Membranes were washed twice in 2Q SSC, 0.1% SDS and 0.2Q SSC, 0.1% SDS at 37 and 60°C, respectively.
Western blot
Supernatant was harvested from 293T cells transfected with HIV-1 NL4.3 and passed through a 0.45 mm ®lter prior to western blot analyses. Protein extracts were prepared by washing cells with phosphate buffered saline (PBS) and lysing in TNT lysis buffer (20 mM Tris/200 mM NaCl/1% Triton X-100) containing protease inhibitors. After 20 min on ice, lysates were spun at 15 000 g for 15 min to remove insoluble material. Protein concentrations were determined by the Bradford procedure. Proteins were resolved on 12% SDS± polyacrylamide gels and transferred onto Hybond PVDF membranes (Amersham, Piscataway, NJ). For sequential probing, blots were stripped in Restore Western Blot Stripping Buffer (Pierce, Rockford, IL). A monoclonal antibody to HIV-1 p24 (183 clone H12-C) was obtained through the NIH AIDS Reagent and Reference program and used at a 1/100 dilution. The monoclonal antibody to a-tubulin (clone DM7 1A) (Sigma, St Louis, MO) was used at a 1/500 dilution. Immunodetection was performed using the peroxidase-based ECL Plus detection system (Amersham) according to the manufacturer's instructions.
RESULTS
siRNA was designed to target the ®rst exon of the HIV-1 tat gene, which encodes a transcriptional transactivator protein that is essential for viral replication. The siRNA sequence was selected based on systematic alignments of computer-predicted secondary structures (mfold 2.0) of overlapping sequences of the tat exon-1. The ®ve lowest free energy structures were analyzed with respect to secondary structure features such as local free energy (DG) of the folded target sequence, the size of single stranded stretches (loops) and the length and stability of stems and helixes. These parameters, among others, have been found to be of predictive value for ribozyme/antisense function (19, 20) . A 21-nt tat siRNA sequence that was conserved among all energy structures was selected for further use.
293T cells, which are permissive for HIV-1 replication, were co-transfected with synthetic tat siRNA. Viral p24 antigen levels were quanti®ed in cell-free supernatant 48 h post transfection. tat siRNA inhibited virus production by 93% compared to tat speci®c sense and antisense RNA (Fig. 2) .
To enable intracellular synthesis of shRNA, we created various expression cassettes that consisted of different upstream promoters (MTD, H1, U6, U6+1, U6+27, CMV) followed by a hairpin region containing tat sense and antisense sequences, which were separated by a 6-nt spacer of irrelevant sequence (Fig. 1) . A DNA construct expressing luciferase speci®c shRNA served as a control vector. A ®ve thymidine transcription termination signal was placed downstream of the hairpin sequence in Pol III promoter driven cassettes. Transcription of the CMV driven expression vector was terminated by a polyadenylation signal.
To test the ef®cacy of the various promoters in expressing tat shRNA, 293T cells were transfected with the indicated expression cassettes (Fig. 1) . Expression levels were analyzed by northern blot using an HIV-1 tat-speci®c oligonucleotide probe. Higher levels of expression were observed with the MTD, U6+1 and U6+27 promoters compared to the U6 and H1 promoters (Fig. 3) . There was no detectable expression with the CMV promoter, con®rming previous reports that an unmodi®ed CMV promoter is not suitable for shRNA expression (21) . The additional 5¢ guanosine in the U6+1 transcript proved to be important for ef®cient priming of transcription, yielding signi®cantly higher expression of tat shRNA when compared to the U6 construct (Fig. 3) .
Given that all Pol III promoters were able to drive the expression of shRNA, we next determined whether promoter choice affected the antiviral activity of tat shRNA. 293T cells were co-transfected with HIV-1 NL4.3 and DNA constructs containing different shRNA expression cassettes. The level of virus production was quanti®ed by measuring viral p24 antigen level in culture supernatant by immunoassay 48 h after transfection. shRNA expressed by the MTD promoter resulted in 93% inhibition of HIV-1 production compared to the MTD-luc control. Signi®cantly, the MTD promoter consistently gave 34±56% greater inhibition of p24 antigen level when compared to the U6+1, U6+27 or H1 promoters (Fig. 4) . Western blot analysis of HIV-1 gag protein in cellfree supernatant and cell lysate con®rmed the p24 ELISA results. The greatest reduction in gag protein in both fractions was achieved using the vector containing the MTD promoter, followed by the U6+1 promoter expression cassette (Fig. 5) . As expected, the CMV promoter did not yield a discernable inhibitory effect on HIV-1 expression.
Given that RNAi acts on a post-transcriptional level, we next assessed the effect of different expression cassettes on total (spliced and unspliced) intracellular HIV-1 RNA by realtime PCR. The degradation of viral RNA mirrored the decrease in viral proteins with the maximum reduction (88%) observed with the MTD promoter. The MTD promoter consistently gave 34±45% greater reduction in total HIV-1 RNA when compared to the U6+1, U6+27 or H1 promoters (Fig. 6) . Finally, the effect of tat shRNA on intracellular unspliced full length HIV-1 RNA expression was determined by northern blot (Fig. 7) . The highest level of HIV-1 RNA degradation was achieved using the MTD and U6+1 shRNA expression cassettes.
DISCUSSION
Our results demonstrate that the potency of HIV-1 speci®c RNAi depends upon the choice of eukaryotic promoter used to drive intracellular expression of shRNA, with the most potent antiviral effects being observed in experiments utilizing the MTD promoter. Our ®ndings con®rm the results of Kawasaki and Taira (22) who compared tRNA Val promoter with human and mouse U6 promoters. These investigators found more effective gene silencing when the tRNA Val promoter was used Variation of RNA input was normalized by GAPDH real-time PCR. To convert threshold cycles to copy number an external standard curve was created with known numbers of HIV-1 in vitro tat transcripts. A vector expressing luciferase speci®c shRNA (MTD-luc) served as a negative control. The greatest antiviral effect was observed in experiments using the MTD promoter, which was adjusted to 100% to allow comparisons with other promoters. Values represent averages of two independent experiments, with the range indicated.
to drive the expression of shRNA targeting K-ras protein (22) . Several factors may contribute to these promoter-dependent effects.
It was previously observed that the effect of synthetic siRNA could be abolished if the RNA included nonbase-paired nucleotide extensions on the 5¢-or 3¢-ends of the duplex RNA. Thus, the stable expression of siRNA from DNA vectors appeared to be dependent on promoters with de®ned transcription initiation and termination sites, such as pol III type III promoters. Of these, the human U6 snRNA and H1, which lie completely upstream of the sequence being transcribed, were successfully introduced to express siRNA and shRNA (1,2). Subsequently, it was shown that the inhibitory effect of shRNA transcripts was not affected by the inclusion of non-speci®c 5¢-end extensions (3). In contrast, it was reasoned that 5¢-end extensions of the precursor hairpin siRNA could stabilize and protect the transcript from 5¢ nuclease attack. For example, the U6+27 promoter, which contains 27 additional nucleotides upstream of the speci®c hairpin siRNA, was found to express transcripts to higher levels than the U6+1 promoter (4).
Promoter elements of tRNA promoters (Type II) are intragenic and co-transcribed as the 5¢ end of the nascent RNA. The MTD promoter is an optimized human tRNAderived promoter modi®ed by the inclusion of an additional 5T termination signal directly downstream of the shRNA sequence (5). The resulting transcript consists of a 100-nt extension of promoter elements upstream of the speci®c hairpin shRNA transcript that is terminated within a stretch of uridine residues. Hairpin precursor RNA must be stabilized against rapid degradation, folded correctly and transported to the cellular compartment where RNAi occurs. The overall secondary structure of the MTD transcript may transfer additional stability to the shRNA and/or improve accessibility of the transcript for the enzyme Dicer to catalyze the initial step of RNAi (23) . Human Dicer is localized in the cell cytoplasm and it has been suggested that additional components of the RNAi pathway are likewise cytoplasmic (24±26). Subcellular localization studies have shown that chimeric tRNA transcripts are predominantly found in cytoplasmic fractions, whereas U6 transcripts are more abundant in the nucleus (14, 22) . Thus, differences in subcellular distribution of precursor transcripts expressed by different promoters could account for variable potencies of shRNA expression units. Therefore, the MTD promoter may be better suited for antiviral RNAi because of its high expression levels of hairpin transcripts, a favorable RNA structure that stabilizes against rapid degradation, and transcripts which are predominantly located in the cytoplasm of the cell.
Interestingly, in our experiments, the expression level of the shRNA transcripts alone did not appear to correlate directly with the magnitude of the antiviral effect. For example, the H1 promoter showed strong inhibition of HIV-1 production, yet had the lowest expression of shRNA in northern blots. Conversely, the U6+27 promoter was associated with strong expression of shRNA, but did not yield concomitantly high suppression of virus production.
RNAi offers investigators a new tool in gene therapy to potentially silence disease-speci®c genes (27) . The effectiveness of permanent transfer of RNAi will depend upon the ef®cient delivery of molecular constructs and maintenance of gene silencing. Given the rapid replication kinetics of HIV-1, a major barrier to using antiviral RNAi is likely to be the emergence of escape variants that contain nucleotide mutations in regions targeted by siRNA. Analogous to drugresistance variants associated with HIV-1 therapy, potent inhibition of viral replication will be required to prevent the generation of such escape variants. To achieve this goal, use of the MTD promoter in adenoviral or retroviral siRNA delivery systems merits further study. 
